MISSION VIEJO, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ:MYND), the market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced that its wholly-owned subsidiary, Arcadian Telepsychiatry Services, was featured on CBS New York by medical correspondent Dr. Max Gomez. Arcadian Telepsychiatry Services manages the delivery of telepsychiatry and tele-mental health services throughout the United States.
As reported by Dr. Max Gomez, mental health is one of the most underserved medical conditions in the country with 1 in 5 Americans believed to be facing a mental health condition at some point in their life. The program highlights the advantages of Arcadian Telepsychiatry Services, which fills a large and growing need for mental health services.
Dr. Michelle Casoli-Reardon, a psychiatrist at Massachusetts General Hospital and part of the Arcadian Telepsychiatry Services provider network, explained that face-to-face technology is perfectly suited to psychiatry. She noted that “as long as I am there with the patient, looking at the patient, I can get everything I need in order to get a really good assessment of the patient.”
Dr. Casoli-Reardon demonstrated MYnd's secure, encrypted and HIPAA compliant system with an actual patient. The segment noted the advantages of the telemedicine system, including that the patient does not have to travel to the provider’s office, and sessions can be scheduled at times that might otherwise be unlikely, and from the comfort of the patient’s own home.
Watch the CBS feature here: http://cbsloc.al/1TyrYPC
Telemedicine is one of the fastest growing areas of healthcare services today and directly addresses the shortage of mental health providers and the growing need for behavioral health services. The American Psychiatric Association estimates that through effective integration of medical and behavioral health services, $26-48 billion could be saved annually.
About Arcadian
Arcadian, manages a suite of services including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. Arcadian utilizes patient engagement and re-engagement strategies so that care is effectively completed, helping to comfortably move inpatient care to outpatient, assisting patients in readjusting to their life routine, as well as reducing wait times for mental health treatment. Arcadian’s customer base includes major health plans, health systems, and community based organizations.
About MYnd Analytics
MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 39,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
Forward-looking Statements
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as statements regarding market developments, new products and growth strategies, Arcadian's ability to reduce patient suffering through increased access to care, Arcadian's ability to use MYnd’s data analytics capabilities to successfully reduce trial and error prescribing, advantages offered by telemedicine, the ability of MYnd’s and Arcadian's products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses, as well as those risks and uncertainties set forth in MYnd's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2017. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.
Contact:
Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: mynd@crescendo-ir.com